权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Boston Biomedical Innovation Center

波士顿生物医学创新中心

基本信息

批准号：
10316833
负责人：
DAVID E. GOLAN
金额：
$ 124.34万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-12-21 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10316833
关键词：
Academia Achievement Address Biological Sciences Biomedical Technology Boston Cardiovascular Diseases Cardiovascular system Clinical Communities Decision Making Development Devices Diagnostic Elements Ensure Entrepreneurship Environment Fruit Funding Goals Government Agencies Healthcare Heart Diseases Hematological Disease Hematology Incentives Individual Infrastructure Institution Knowledge Lung Lung diseases Medical Medicine Mentors Mission National Heart, Lung, and Blood Institute Patients Private Sector Process Public Sector Rare Diseases Research Personnel Resources Rewards Secure Seeds Sleep Sleep Disorders Societies Speed Technology Therapeutic Time Translational Research Translations clinical application clinical practice commercialization diagnostic technologies experience heuristics innovation invention meetings new technology public-private partnership success tool validation studies

项目摘要

A well-recognized gap exists in the path from biomedical discovery in academia to clinical application and commercialization of therapeutic, device, and diagnostic technologies in cardiovascular, pulmonary, hematologic, and sleep disorders. This chasm is the result of inadequate funding for support of proof-of-concept or validation studies essential for early stage development; insufficient access to the resources and expertise needed to develop new technologies; and a lack of knowledge and experience among academic investigators in bringing new ideas to commercial realization. Within the partnering institutions included in this application, the essential elements exist with which to build the infrastructure needed to support and sustain the uninterrupted, durable flow of inventions from discovery through development and commercialization. While these institutions have a clear track record of remarkably successful development of many biomedical technologies, most of these commercial successes have been achieved by the tenacity of individual inventors rather than with the help of committed institutional mechanisms. We proposed to address these key shortcomings by establishing the regional Boston Center for Accelerated Innovation in Therapeutics, Devices, and Diagnostics for Heart, Lung, Blood, and Sleep Disorders (B-BIC, or the Boston Biomedical Innovation Center). The key objectives of this Center are to: 1) develop an integrated infrastructure that would expand the universe of commercializable technologies for heart, lung, blood, and sleep disorders; 2) place these opportunities in the proper evaluative context through an engagement ("seed it"), solicitation ("find it"), and selection ("pick it") strategy; 3) efficiently and effectively bring those selected to an appropriate exit point from the development process; and 4) provide the educational and mentoring infrastructure necessary for the development of the proper entrepreneurial skills among academic innovators. By achieving these goals, B-BlC would change the culture of our academic environment, as well as the relationship between the public and private sectors in facilitating successful development strategies for technologies in heart, lung, blood, and sleep disorders for the ultimate benefit of patients and society.

在从学术界的生物医学发现到临床应用的道路上，存在着众所周知的差距心血管、肺、肺等领域的治疗、设备和诊断技术的商业化血液学和睡眠障碍。这种鸿沟是支持概念验证的资金不足的结果。或对早期开发至关重要的验证研究；没有足够的资源和开发新技术所需的专业知识；以及学术界缺乏知识和经验研究人员将新想法带到商业实现中。在合作机构中包括此应用程序是构建基础设施所需的基本要素，支持和保持发明从发现到开发的不间断、持久的流动商业化。虽然这些机构有着非常成功的发展的明确记录在许多生物医学技术中，这些商业成功中的大多数都是通过坚韧不拔的而不是在承诺的体制机制的帮助下。我们提议通过在#年建立地区波士顿加速创新中心来解决这些关键缺陷心、肺、血液和睡眠障碍的治疗、设备和诊断(B-BIC或波士顿生物医学创新中心)。该中心的主要目标是：1)开发一个完整的基础设施将扩大心脏、肺、血液和血液等可商业化技术的宇宙睡眠障碍；2)通过参与将这些机会置于适当的评估环境中 IT“)、征集(”Find It“)和选择(”Pick It“)策略；3)高效和有效地将那些被选中的人带到开发过程的适当退出点；以及4)提供教育和指导在学术界开发适当的创业技能所需的基础设施创新者。通过实现这些目标，B-BLC将改变我们的学术环境的文化，如以及公营部门和私营部门在促进成功发展方面的关系心、肺、血液和睡眠障碍方面的技术战略，最终造福于患者和社会。

项目成果

期刊论文数量（8）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（2）

"Rogue" neutrophil-subset [DEspR+CD11b+/CD66b+] immunotype is an actionable therapeutic target for neutrophilic inflammation-mediated tissue injury - studies in human, macaque and rat LPS-inflammation models.

DOI：
10.3389/fimmu.2022.1008390
发表时间：
2022
期刊：
Frontiers in immunology
影响因子：
7.3
作者：
通讯作者：

An Intracardiac Soft Robotic Device for Augmentation of Blood Ejection from the Failing Right Ventricle.

DOI：
10.1007/s10439-017-1855-z
发表时间：
2017-09
期刊：
Annals of biomedical engineering
影响因子：
3.8
作者：
Horvath MA;Wamala I;Rytkin E;Doyle E;Payne CJ;Thalhofer T;Berra I;Solovyeva A;Saeed M;Hendren S;Roche ET;Del Nido PJ;Walsh CJ;Vasilyev NV
通讯作者：
Vasilyev NV

Using artificial intelligence to avoid human error in identifying embryos: a retrospective cohort study.

使用人工智能避免识别胚胎时的人为错误：一项回顾性队列研究。

DOI：
10.1007/s10815-022-02585-y
发表时间：
2022
期刊：
Journal of assisted reproduction and genetics
影响因子：
3.1
作者：
Hammer,KarissaC;Jiang,VictoriaS;Kanakasabapathy,ManojKumar;Thirumalaraju,Prudhvi;Kandula,Hemanth;Dimitriadis,Irene;Souter,Irene;Bormann,CharlesL;Shafiee,Hadi
通讯作者：
Shafiee,Hadi

A spatially uniform illumination source for widefield multi-spectral optical microscopy.